特殊状态人群中亚胺培南-西司他丁的群体药动学研究进展
x

请在关注微信后,向客服人员索取文件

篇名: 特殊状态人群中亚胺培南-西司他丁的群体药动学研究进展
TITLE: Research advance of population pharmacokinetics of imipenem-cilastatin in special status populations
摘要: 亚胺培南-西司他丁为广谱碳青霉烯类抗菌药物,已在临床广泛应用,但其在特殊状态人群[本文特指连续性肾脏替代治疗(CRRT)患者、体外膜肺氧合(ECMO)患者、病情危重的烧伤患者以及新生儿和儿童]的个体化给药方案制订中缺乏相应指南和专家共识。本文总结亚胺培南-西司他丁在特殊状态人群中的群体药动学研究,推荐亚胺培南-西司他丁剂量为:CRRT患者给予1~3g/d;烧伤患者给予500mg~1g,q6h;ECMO患者给予750mg~1g,q6h;新生儿给予20mg/kg,q8h或25mg/kg,q8h;儿童给予25mg/kg,q6h。
ABSTRACT: Imipenem-cilastatin is a broad-spectrum carbapenem antibiotic drug that has been widely used in clinical practice , but there is a lack of guidelines and expert consensus on the development of individualized regimens for special status populations [e.g. continuous renal replacement therapy (CRRT)patients,extracorporeal membrane oxygenation (ECMO)patients, critically ill burn patients ,neonates and children]. In this paper ,by searching population pharmacokinetics research of imipenem- cilastatin in special status populations ,it is recommended that imipenem-cilastatin is given 1 to 3 g/d for CRRT patients ;500 mg to 1 g,q6 h for burn patients ;750 mg to 1 g,q6 h for ECMO patients ;20 mg/kg or 25 mg/kg,q8 h for neonates ;and 25 mg/kg,q6 h for children.
期刊: 2022年第33卷第09期
作者: 左建丽,何瑶,李福书,陈兴,郑晓媛
AUTHORS: ZUO Jianli,HE Yao,LI Fushu,CHEN Xing,ZHENG Xiaoyuan
关键字: 亚胺培南-西司他丁;群体药动学;连续性肾脏替代治疗;体外膜肺氧合;危重症;特殊人群;剂量优化
KEYWORDS: Imipenem-cilastatin;population pharmacokinetics ;continuous renal replacement therapy ;extracorporeal membrane
阅读数: 24 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!